Description: Read the March 2017 issue of Health Watch, published by the Health Section. Practical information for actuaries, articles impact sections, section activities.

Description: Hear from the chairperson on themes in the March 2017 issue of Health Watch, published by the Health Section.

Description: Interview with Paul Ginsburg, president of the Center for Studying Health System Change.

Description: Medicaid and the ACA

Description: This article talks about the new onsite clinic at Hewitt and how it benefits employees and employers.

Description: This article discusses how medicine is now inextricably linked with genomics, and within the clinical community the call is out for frontline physicians to become familiar with genetic science.

Description: The article provides insights about the need for revolutionary actuaries in Saudi Arabia due to the reform that is happening across the kingdom under all sectors. Then I talk briefly about the health sector and the transformation that is happing in the sector, and how qualified health actuaries can contribute to this health reform.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This article examines the dynamic environment of the health care system in the United States and the challenges facing the health actuary.

Description: In this paper, we shine a light on the global public health epidemic of intimate partner violence (IPV). This first paper presents background information on the problem with a focus on health and economic impacts for the actuarial audience